Boston Scientific (BSX) Tops Q1 EPS by 1c; Lifts Outlook

Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.33, $0.01 better than the analyst estimate of $0.32. Revenue for the quarter came in at $2.38 billion versus the consensus estimate of $2.34 billion.

GUIDANCE:

Boston Scientific sees FY2018 EPS of $1.37-$1.41, versus $1.35-$1.41 prior and the consensus of $1.37. Boston Scientific sees FY2018 revenue of $9.75-9.9 billion, versus $9.65-$9.8 billion prior and the consensus of $9.75 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• Citi cuts Boston Scientific rating to neutral, lowers price target
• Citi downgrades Boston Scientific on uncertain recovery path
• Boston Scientific (BSX) call put ratio 1.8 calls to 1 put with a focus on 25K contracts of December 75 calls